| Literature DB >> 35574236 |
Wanis H Ibrahim1, Shaikha D Al-Shokri2, Musa S Hussein1, Lana M Abu Afifeh3, Gowri Karuppasamy1, Jessiya V Parambil4, Farras M Elasad1, Mohammed E Faris1, Mohamed S Abdelghani1, Ahmed Abdellah1, Antoun Kamel1, Hafedh Ghazouani1, Mushtaq Ahmad1, Aisha Aladab1, Mohammed I Danjuma1, Tasleem Raza1.
Abstract
BACKGROUND: Acute pulmonary embolism (PE) is a common and potentially life-threatening condition. This comprehensive study from a Gulf Cooperation Council (GCC) country aimed to evaluate the clinical, radiological, and outcome characteristics associated with acute PE.Entities:
Keywords: Venous thromboembolism; clinical features; mortality; pulmonary embolism
Year: 2022 PMID: 35574236 PMCID: PMC9083188 DOI: 10.5339/qmj.2022.1
Source DB: PubMed Journal: Qatar Med J ISSN: 0253-8253
General characteristics of the study population
| Variables | Frequency (N) | (%) |
|
| ||
| Gender (n = 436) | ||
|
| ||
| Male | 231 | 53.0% |
|
| ||
| Female | 205 | 47.0% |
|
| ||
| Nationality (n = 436) | ||
|
| ||
| Qatari | 117 | 26.8% |
|
| ||
| Non-Qatari | 319 | 73.2% |
|
| ||
| Age (years) (n = 436) | ||
|
| ||
| Median age (years) (IQR*) | 47(35–61) | |
|
| ||
| < 30 | 55 | 12.6% |
|
| ||
| 30–39 | 96 | 22.0% |
|
| ||
| 40–49 | 93 | 21.3% |
|
| ||
| 50–59 | 74 | 17.0% |
|
| ||
| 60–69 | 52 | 11.9% |
|
| ||
| ≥ 70 | 66 | 15.1% |
|
| ||
| Where did PE happen? (n = 436) | ||
|
| ||
| Outside hospital | 299 | 68.6% |
|
| ||
| In-hospital | 137 | 31.4% |
|
| ||
| In-hospital PE (place) (n = 137) | ||
|
| ||
| Surgical ward | 89 | 65.0% |
|
| ||
| Medical ward | 48 | 35.0% |
|
| ||
| VTE* prophylaxis used before development of in-hospital PE (n = 79) | ||
|
| ||
| Unfractionated heparin | 14 | 17.7% |
|
| ||
| LMW Heparin** | 23 | 29.1% |
|
| ||
| Pneumatic compressions | 7 | 8.9% |
|
| ||
| No VTE prophyalxis | 32 | 40.5% |
|
| ||
| Others (warfarin) | 3 | 3.8% |
|
| ||
*VTE, venous thromboembolism
**LMW, low molecular weight
Baseline comorbidities of the study population (n = 436)
| Variables | N | % |
|
| ||
| Obesity (BMI>30*) | 151 | 34.6% |
|
| ||
| Hypertension | 128 | 29.4% |
|
| ||
| Diabetes | 109 | 25.0% |
|
| ||
| Smoking | 55 | 12.6% |
|
| ||
| Ischemic heart disease | 31 | 7.1% |
|
| ||
| Stroke | 24 | 5.5% |
|
| ||
| Alcohol intake | 18 | 4.1% |
|
| ||
| Congestive heart failure | 17 | 3.9% |
|
| ||
| Asthma | 17 | 3.9% |
|
| ||
| OSA** | 12 | 2.8% |
|
| ||
| COPD*** | 11 | 2.5% |
|
| ||
| Interstitial lung disease | 5 | 1.1% |
|
| ||
*BMI, body mass index
**OSA, obstructive sleep apnea
***COPD, chronic obstructive pulmonary disease
Risk factors for PE (n = 436)
| Variables | N | % |
|
| ||
| Family history of thrombosis Recent long trip Immobilization Recent hospitalization for surgery Recent hospitalization for a medical reason Thrombophilia Recent fracture Active cancer Pregnancy Use of OCP* | 16 52 113 90 48 33 55 54 14 23 | 3.7% 11.9% 25.9% 20.6% 11.0% 7.6% 12.6% 12.4% 3.2% 5.3% |
|
| ||
*OCP, oral contraceptive pills
Clinical presentation and severity of PE
| Chief presenting symptom (n = 405) | ||
|
| ||
| Dyspnea | 160 | 39.5% |
|
| ||
| Chest pain | 123 | 30.4% |
|
| ||
| Syncope | 19 | 4.7% |
|
| ||
| No symptoms | 18 | 4.4% |
|
| ||
| Palpitations | 11 | 2.7% |
|
| ||
| Dizziness | 10 | 2.5% |
|
| ||
| Hemoptysis | 10 | 2.5% |
|
| ||
| Cough | 9 | 2.2% |
|
| ||
| Cardiac arrest | 9 | 2.2% |
|
| ||
| Arrhythmia | 1 | 0.2% |
|
| ||
| Others (abdominal pain/reduced oral intake/fever) | 35 | 8.6% |
|
| ||
| Duration of symptoms (n = 369) | ||
|
| ||
| < 1 h | 38 | 10.3% |
|
| ||
| 1–2 h | 14 | 3.8% |
|
| ||
| 2–12 h | 3 | 0.8% |
|
| ||
| 12–24 h | 2 | 0.5% |
|
| ||
| 1–7 days | 270 | 73.2% |
|
| ||
| >7 days | 42 | 11.4% |
|
| ||
| Signs of PE (n = 436) | ||
|
| ||
| Tachypnea (PR>20*) | 196 | 45.0% |
|
| ||
| Tachycardia (RR>100**) | 217 | 49.8% |
|
| ||
| JVP*** distension | 5 | 1.1% |
|
| ||
| Pitting leg edema | 35 | 8.0% |
|
| ||
| Parasternal heave | 4 | 0.9% |
|
| ||
| S3 gallop | 2 | 0.5% |
|
| ||
| Clinical signs of DVT $ | 69 | 15.8% |
|
| ||
| Oxygen saturation%: Mean (min–max) | 95 (60–100) | |
|
| ||
| PE severity classification (n = 436) | ||
|
| ||
| Low-risk PE | 217 | 49.8% |
|
| ||
| Intermediate-risk PE | 137 | 31.4% |
|
| ||
| High-risk PE | 82 | 18.8% |
|
| ||
*PR, pulse rate
**RR, respiratory rate
***JVP, jugular venous pressure
$ DVT, deep vein thrombosis
Radiologic and laboratory findings
| Variables | N | % |
|
| ||
| Findings on chest radiograph (n = 366) | ||
|
| ||
| Normal chest X-Ray | 150 | 41.0% |
|
| ||
| Pleural effusion | 93 | 25.4% |
|
| ||
| Atelectasis | 79 | 21.6% |
|
| ||
| Oligemia (Westermark sign) | 60 | 16.4% |
|
| ||
| Pleural-based opacity (Hampton hump) | 46 | 12.6% |
|
| ||
| Prominent central pulmonary artery (Fleischner sign) | 6 | 1.6% |
|
| ||
| Location of the PE on CTPA* (n = 426) | ||
|
| ||
| Central | 158 | 37.1% |
|
| ||
| Lobar | 60 | 14.1% |
|
| ||
| Segmental | 176 | 41.3% |
|
| ||
| Subsegmental | 32 | 7.5% |
|
| ||
| Lung involved on CTPA (n = 432) | ||
|
| ||
| Bilateral PE | 277 | 64.1% |
|
| ||
| Left-sided PE | 52 | 12.0% |
|
| ||
| Right-sided PE | 103 | 23.8% |
|
| ||
| Laboratory findings Median (Min–Max) | ||
|
| ||
| Troponin T (N: 3–15 ng/L) (n = 213) | 24 (10–103.5) | |
|
| ||
| NT-Pro-BNP** (N: 0–376 pg/mL) (n = 224) | 2063 (1200–3575) | |
|
| ||
| D-dimer (N: 0–0.49 mg/L) (n = 279) | 5.15 (2.7–10.64) | |
|
| ||
*CTPA, computed tomography pulmonary angiography
**NT-Pro-BNP, NT-proB-type natriuretic peptide
Echocardiographic and electrocardiographic findings
| Echocardiographic findings (n=327) | ||
|
| ||
| Right ventricular dysfunction | 85 | 26.0% |
|
| ||
| Right ventricular enlargement | 119 | 36.4% |
|
| ||
| Right ventricular hypokinesis | 67 | 20.5% |
|
| ||
| Tricuspid regurgitation | 112 | 34.2% |
|
| ||
| RVSP (mmHg) (n = 279) | ||
|
| ||
| Mean | 42 ± 17 | |
|
| ||
| RVSP ≥ 40 * | 158 56.6% | |
|
| ||
| RVSP>40 | 121 43.4% | |
|
| ||
| ECG abnormalities (n = 192) | ||
|
| ||
| Tachycardia | 188 | 97.9% |
|
| ||
| Right Axis deviation | 23 | 12.0% |
|
| ||
| Positive R in V1 | 22 | 11.5% |
|
| ||
| T inversion in V1–V4 | 57 | 29.7% |
|
| ||
| ST segment depression in V1–V4 | 24 | 12.5% |
|
| ||
| S1-Q3-T3 Pattern | 58 | 30.2% |
|
| ||
*RVSP, right ventricular systolic pressure
Treatment received (initial and maintenance)
| Variables | N | % |
|
| ||
| Initial treatment (n = 436) | ||
|
| ||
| Thrombolysis | 36 | 8.3% |
|
| ||
| Thrombectomy | 2 | 0.5 |
|
| ||
| Unfractionated heparin | 66 | 15.0% |
|
| ||
| LMW* heparin | 290 | 66.5% |
|
| ||
| DOAC** | 20 | 4.6% |
|
| ||
| Fondaparinux | 1 | 0.2% |
|
| ||
| IVC filter *** | 21 | 4.8% |
|
| ||
| Maintenance treatment (n = 380) | ||
|
| ||
| Warfarin | 166 | 43.7% |
|
| ||
| DOAC | 167 | 43.9% |
|
| ||
| LMW heparin | 47 | 12.4% |
|
| ||
*LMW, low molecular weight
**DOAC, directly acting oral anticoagulan
***IVC, inferior vena cava
Complications at follow-up (0–6 months) (n = 436)
| Variables | N | % |
|
| ||
| Mortality | 15 | 3.4% |
|
| ||
| PE recurrence | 21 | 4.8% |
|
| ||
| CTEPH* | 22 | 5.0% |
|
| ||
| Minor bleeding | 61 | 14.0% |
|
| ||
| Major bleeding | 22 | 5.0% |
|
| ||
*CTEPH: chronic thromboembolic pulmonary hypertension